Cibus (CBUS) investor relations material

Executive summary

• Achieved significant regulatory and commercial milestones in 2025, including EU political agreement on gene editing, UK partnership selection, and technology leadership in gene editing for agriculture and ingredients.

• Advanced Rice program with seven partners, targeting 2027 LATAM and 2028 USA launches, with over $200 million peak annual royalty potential and received first payment from the sustainable ingredients program.

• Selected as a technology partner by the UK government and benefited from EU political agreement on New Genomic Techniques legislation.

• Transitioned to a commercially driven model, focusing on predictable, time-bound trait development and deeper integration with seed companies.

• Expanded global reach, targeting high-growth markets in Latin America, India, and Asia, and building a pipeline of ongoing gene editing partnerships.

Financial highlights

• Cash and cash equivalents were $9.9 million as of December 31, 2025; raised $22.3 million in January 2026, extending runway into late Q3 2026.

• Reduced operating expenses by approximately $10 million in 2025 through cost-saving initiatives.

• R&D expense was $9.4 million (down from $12.4 million YoY); SG&A expense was $5.1 million (down from $6.8 million YoY).

• Net loss for Q4 2025 was $31.9 million, compared to $25.8 million in Q4 2024; full-year net loss was $132.2 million, improved from $282.7 million in 2024.

• Q4 2025 revenue was $1.1 million, down from $1.2 million in Q4 2024; full-year 2025 revenue was $3.6 million, down from $4.3 million in 2024.

Outlook and guidance

• On track for initial rice market entry in Latin America in 2027, U.S. expansion in 2028, and India/Asia launch around 2030.

• Targeting commercial scale production of sustainable biofragrance ingredients in 2026, with $20–$40 million annual royalty potential.

• Focused on execution and momentum in 2026, with key milestones in rice, sustainable ingredients, and regulatory developments.

• Disciplined capital allocation aims to reduce annual net cash usage to ~$30 million or less in 2026.

• Board and advisors evaluating strategic alternatives to maximize shareholder value.